Janssen to Address NICE's Concerns Following Another English Funding No For Spravato

UK health technology assessment body NICE says the cost-effectiveness estimates for the nasal spray for treating hard-to-treat depression are much higher than what it considers to be cost-effective.

Target
J&J gets another go with NICE for Spravato • Source: Shutterstock

The UK's National Institute for Health and Care Excellence (NICE) has for the second time recommended against making Janssen's antidepressant spray Spravato (esketamine) available on England's National Health Service. 

More from Health Technology Assessment

More from Market Access

Navigating the Unknown: EU HTA Regulation’s Impact On Commercial Confidentiality

 

Company dossiers submitted for EU-level joint clinical assessments under the Health Technology Assessment Regulation will be made public. This could conflict with other strategic business decisions and should be planned for in advance, experts say.

Tipping Point: Tariffs Create Uncertainty, Risk Long-Term Price Increases, Shortages

 
• By 

President Trump’s 10% tariff on active pharmaceutical ingredients and finished dosage forms could push some generic drug makers to exit therapeutic categories if they cannot absorb the new costs, which could lead to shortages.

US Medicare Agency Brings Back Familiar Faces For Trump 2.0

 

Several first-term Trump veterans are returning to leadership roles at the US Centers for Medicare and Medicaid Services ahead of the expected confirmation of Mehmet Oz to lead the agency.